AMVAC Acquires Andersons' FFIII™ Fungicide Product Line

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- AMVAC Chemical Corporation, a wholly owned subsidiary of American Vanguard Corporation (NYSE: AVD), has acquired the FFIII™ fungicide product line from the Plant Nutrient Group of The Andersons, Inc, (NASDAQ: ANDE). FFIII contains three highly effective active ingredients which work together to provide long lasting turf disease protection.

Mr. Jeff Alvis, the Business Manager of AMVAC’s AEP (non-crop) business segment commented: “We are delighted to have this excellent fungicide incorporated into our expanding portfolio of products for turf preservation. FFIII is a trusted granular fungicide for the prevention of Pink and Gray Snow Mold and as a dry granular formulation it spreads evenly and provides a very high level of application control. We intend to continue the excellent marketing and distribution efforts begun by The Andersons, and our turf management customers will benefit from the combination of performance and convenience that FFIII facilitates.”

Bob Eichenberg, Director of Sales for the Turf business at The Andersons added: “FFIII is an excellent granular applied product for snow mold control. AMVAC is a market leader in this category and we are confident they will steward the product well into the future.”

About American Vanguard

American Vanguard Corporation is a diversified specialty and agricultural products company that develops and markets products for crop protection and management, turf and ornamentals management and public and animal health. American Vanguard is included on the Russell 2000® & Russell 3000® Indexes and the Standard & Poors 600 Index. To learn more about American Vanguard, please reference the Company’s web site at www.american-vanguard.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170117005531/en/

AMVAC-Chemical – AEP:
Jeff Alvis
Business Manager
[email protected]
or
American Vanguard:
William Kuser, 949-260-1200
Director of Investor Relations
[email protected]

Source: American Vanguard Corporation

You May Also Be Interested In

• Stabilization Notice
• PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
• Fraser Institute News Release: Ontario curricula for Grades 1 to 12 lacking in Canadian history